Add new comment

Photography bula da injeo duo-decadron The panel vote amounts to a recommendation that the FDA approve Perjeta for use in early-stage breast cancer. The FDA usually follows the advice of its panels but isn’t required to. FDA is expected to make a decision by Oct. 31.